Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

NCT06590961 is registered in ClinicalTrials.gov with Ubix Therapeutics, Inc. as lead sponsor.

NCT NCT06590961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Lead sponsor
Ubix Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 20, 2025
Completion date
August 31, 2027
Enrollment
94 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell malignancies